Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
Authors:
- Rafli van de LaarRLRafli van de Laar
- Petra Lm ZusterzeelPZPetra Lm Zusterzeel
- Toon Van GorpTGToon Van Gorp
- Marrije R BuistMBMarrije R Buist
- Willemien J van DrielWDWillemien J van Driel
- Katja N GaarenstroomKGKatja N Gaarenstroom
- Henriette Jg ArtsHAHenriette Jg Arts
- Johannes Cm van HuisselingJHJohannes Cm van Huisseling
- Ralph Hm HermansRHRalph Hm Hermans
- Johanna Ma PijnenborgJPJohanna Ma Pijnenborg
- Eltjo Mj SchutterESEltjo Mj Schutter
- Harold Mp PelikanHPHarold Mp Pelikan
Open Access
- 14 January 2014
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 22
Abstract
Improvement in treatment for patients with recurrent ovarian cancer is needed. Standard therapy in patients with platinum-sensitive recurrent ovarian cancer consists of platinum-based chemotherapy. Median overall survival is reported between 18 and 35 months. Currently, the role of surgery in recurrent ovarian cancer is not clear. In selective patients a survival benefit up to 62 months is reported for patients undergoing complete secondary cytoreductive surgery. Whether cytoreductive surgery in recurrent platinum-sensitive ovarian cancer is beneficial remains questionable due to the lack of level I-II evidence.Keywords
This publication has 13 references indexed in Scilit:
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerJournal of Clinical Oncology, 2012
- Clinical Trials in Recurrent Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecological Cancer, 2011
- Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancerEuropean Journal of Surgical Oncology, 2010
- Cytoreductive surgery for recurrent ovarian cancer: A meta-analysisGynecologic Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR TrialAnnals of Surgical Oncology, 2006
- Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancerInternational Journal of Gynecological Cancer, 2005
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003